A method for producing a liquid crystalline drug delivery system, the method comprising: forming a first solution containing a lipidic component and an alcohol, the first solution being maintained at a temperature of 40 to 55 °C; dissolving an active pharmaceutical ingredient into the first solution, wherein the API is selected from the group consisting of fluticasone propionate, dexamethasone, betamethasone, budesonide, triamcinolone acetonide, methyl prednisolone, cortisone, beclometasone, fluticasone furoate, deoxycorticosterone acetate, loteprednol etabonate, difluprednate, fluorometholone, rimexolone, travoprost, azithromycin, moxifloxacin, netilmycin, nepafenac, diclofenac, posaconazole, prednisolone acetate and a combination thereof; obtaining a second solution that includes a mucoadhesive hydrophilic polymer and a buffer, the second solution being aqueous and maintained at a temperature of 5 to 55 °C; mixing the first solution and the second solution to form a combined nano/micro-dispersion, the mixing accomplished by a high energy mixing process selected from sonication, high shear mixing and a combination thereof; subjecting the combined nano/micro-dispersion to microfluidization to form a nano-dispersion; and incubating the nano-dispersion at 2-5 °C to form a liquid crystalline drug delivery system, wherein a weight ratio between the first solution and the second solution is 1:1 to 1:15, wherein the lipidic component includes phosphatidylcholine and medium chain triglycerides, wherein the alcohol is cetyl alcohol, and wherein the mucoadhesive hydrophilic polymer is selected from the group consisting of sodium hyaluronate, xanthan gum, guar gum, carboxymethyl cellulose, 1-4 beta glucan, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide), tamarind seed polysaccharide, sodium alginate, polycarbopol, polycarbophil, and a mixture thereof. forming a first solution containing a lipidic component and an alcohol, the first solution being maintained at a temperature of 40 to 55 °C; dissolving an active pharmaceutical ingredient into the first solution, wherein the API is selected from the group consisting of fluticasone propionate, dexamethasone, betamethasone, budesonide, triamcinolone acetonide, methyl prednisolone, cortisone, beclometasone, fluticasone furoate, deoxycorticosterone acetate, loteprednol etabonate, difluprednate, fluorometholone, rimexolone, travoprost, azithromycin, moxifloxacin, netilmycin, nepafenac, diclofenac, posaconazole, prednisolone acetate and a combination thereof; obtaining a second solution that includes a mucoadhesive hydrophilic polymer and a buffer, the second solution being aqueous and maintained at a temperature of 5 to 55 °C; mixing the first solution and the second solution to form a combined nano/micro-dispersion, the mixing accomplished by a high energy mixing process selected from sonication, high shear mixing and a combination thereof; subjecting the combined nano/micro-dispersion to microfluidization to form a nano-dispersion; and incubating the nano-dispersion at 2-5 °C to form a liquid crystalline drug delivery system, wherein a weight ratio between the first solution and the second solution is 1:1 to 1:15, wherein the lipidic component includes phosphatidylcholine and medium chain triglycerides, wherein the alcohol is cetyl alcohol, and wherein the mucoadhesive hydrophilic polymer is selected from the group consisting of sodium hyaluronate, xanthan gum, guar gum, carboxymethyl cellulose, 1-4 beta glucan, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide), tamarind seed polysaccharide, sodium alginate, polycarbopol, polycarbophil, and a mixture thereof.